12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: Phase III started

Seattle Genetics began an open-label, international Phase III trial to compare 1.8 mg/kg IV Adcetris every 21 days for up to 48 weeks vs. investigator's choice of methotrexate or bexarotene in about 124 CD30-positive CTLC patients, including those with primary cutaneous anaplastic large cell lymphoma or mycosis fungoides. The trial has a...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >